Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia
Crossref DOI link: https://doi.org/10.1007/s12185-016-2071-6
Published Online: 2016-07-26
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hino, Akihisa
Yoshida, Hitoshi
Tada, Yuma
Koike, Midori
Minami, Ryota
Masaie, Hiroaki
Ishikawa, Jun
License valid from 2016-07-26